Home / Intelligence / Webinars / Generating Robust Insights to Develop a Compelling Value Story with RWE
Available On Demand
The unprecedented availability of rich RWE data sources gives HEOR, Value and Access and Medical leaders the opportunity to be more intentional than ever before. High-quality, compelling evidence is now a necessity, not just for high-value therapies playing in the rare disease space—but also more broadly, to show reduced unmet needs, health care resource utilization (HCRU) and cost offsets.
Deep experience using industry-leading data sources, tech-enabled methodologies and therapeutic expertise allow Trinity experts to choose the right data for each client situation and create foundational analyses today that will continue to support your questions in the future and drive downstream publications.
Key Webinar Topics
- Which data sources have the greatest utility for each specific therapeutic area and type of asset?
- How—and when—can they be leveraged pre- and post-launch?
- How should disparate data sources be linked/combined to maximize insights?
- How can ROI be maximized on data acquisition and RWE insights?
Featuring
Matt O’Hara
Partner,
Evidence Strategy
Jeff Skaar
Managing Director,
Evidence Strategy
Sri Saikumar
Associate Principal,
Real World Evidence
Complete the form below to view the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Blog
Learnings to Kick-Start 2025: Joint Clinical Assessments and Health Technology Assessments
One trend Trinity Life Sciences has observed and that was reinforced by stakeholders at ISPOR EU is the importance of evidence in healthcare decision-making. This trend was highlighted particularly in the context of joint clinical assessments (JCA) and health technology assessments (HTA). Trinity presented 11 posters at ISPOR EU, 6 of which focused on HTA and/or […]
Read More
Blog
Solving the Cell & Gene Therapy Access Puzzle in the U.S.
Cell and gene therapies (CGTs) have ushered in a new era of medicine, offering patients transformative, even potentially curative solutions, with a single treatment. Despite the clinical promise, barriers to patient access remain given administration complexity, gaps in patient outcome evidence and high costs. As cell and gene therapies become available in new indications beyond […]
Read More
Blog
5 Key Trends in Global Market Access
Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacted in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various pricing and market access landscapes. Trinity is closely monitoring the evolving global advanced therapeutics […]
Read More